Photo of Michael C. Heinrich, M.D.

Michael C. Heinrich M.D.

    • Professor of Medicine School of Medicine
    • Cell and Developmental Biology Graduate Program School of Medicine
    • Cancer Biology Graduate Program School of Medicine
    • Program in Molecular and Cellular Biosciences School of Medicine

Dr. Heinrich's research includes both preclinical identification of novel molecular targets and testing of new agents in the laboratory and the clinic. This includes both genomics research using high-throughput gentoyping to identify oncogenic mutations and testing of new compounds in cellular and biochemical assays. Dr. Heinrich’s laboratory is particularly expert in the analysis of inhibitors of oncogenic receptor tyrosine kinases such as KIT, PDGFRA and FLT3.

Education

  • M.D., Johns Hopkins University School of Medicine, 0 1984
  • Residency:

    • Oregon Health & Science University, 1988
  • Fellowship:

    • Hematology/medical oncology, Oregon Health & Science University, 1991
  • Certifications:

    • American Board of Internal Medicine, (internal medicine) 1987

Memberships and associations

  • American Society of Clinical Oncology

Publications

  • "Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results : Analysis of Phase 3 SWOG Intergroup Trial S0033." JAMA oncology In: , Vol. 3, No. 7, 01.07.2017, p. 944-952.
  • "Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors." Expert Review of Molecular Diagnostics In: , Vol. 17, No. 5, 04.05.2017, p. 445-457.
  • "MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation." Nature Communications In: , Vol. 8, 14674, 08.03.2017.
  • "PDGFRA Antibody for Soft Tissue Sarcoma." Cell In: , Vol. 168, No. 4, 09.02.2017, p. 555.
  • "Defining the impact of adjuvant therapy in molecularly defined subsets of gastrointestinal stromal tumor : From lumping to splitting." JAMA Oncology In: , Vol. 3, No. 5, 2017, p. 597-599.
  • "FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors." Journal of Translational Medicine In: , Vol. 14, No. 1, 339, 14.12.2016.
  • "Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy." Annals of Oncology  In: , Vol. 27, No. 9, mdw228, 01.09.2016, p. 1794-1799.
  • "Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour." European Journal of Cancer  In: , Vol. 61, 01.07.2016, p. 94-101.
  • "Regorafenib for treatment of imatinib- and sunitinib-resistant metastatic gastrointestinal stromal tumors." Expert Opinion on Orphan Drugs In: , 09.05.2016, p. 1-12.
  • "Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial." BMC Cancer In: , Vol. 16, No. 1, 22, 15.01.2016.
  • "S0502 : A SWOG phase III randomized study of imatinib, with or without bevacizumab, in patients with untreated metastatic or unresectable gastrointestinal stromal tumors." Oncologist  In: , Vol. 20, No. 12, 17.11.2015, p. 1353-1354.
  • "SDHC methylation in gastrointestinal stromal tumors (GIST) : A case report." BMC Medical Genetics In: , Vol. 16, No. 1, 87, 28.09.2015.
  • "Genotyping and immunohistochemistry of gastrointestinal stromal tumors : An update." Seminars in Diagnostic Pathology In: , Vol. 32, No. 5, 01.09.2015, p. 392-399.
  • "KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GI stromal tumors : Relevance of concomitant phosphatidylinositol 3-kinase/AKT dysregulation." Journal of Clinical Oncology In: , Vol. 33, No. 22, 01.08.2015, p. e93-e96.
  • "Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition." Clinical Cancer Research  In: , Vol. 21, No. 10, 15.05.2015, p. 2289-2296.
  • "Crosstalk between KIT and FGFR3 promotes gastrointestinal stromal tumor cell growth and drug resistance." Cancer Research In: , Vol. 75, No. 5, 01.03.2015, p. 880-891.
  • "Quadruple wild-type (WT) GIST : Defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways." Cancer Medicine In: , Vol. 4, No. 1, 01.01.2015, p. 101-103.
  • "Combination therapy for KIT-mutant mast cells : Targeting constitutive NFAT and KIT activity." Molecular Cancer Therapeutics In: , Vol. 13, No. 12, 01.12.2014, p. 2840-2851.
  • "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients." Clinical Cancer Research In: , Vol. 20, No. 22, 15.11.2014, p. 5745-5755.
  • "Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST)." BMC Cancer In: , Vol. 14, No. 1, 685, 20.09.2014.
  • "Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor : The ACOSOG Z9001 trial." Journal of Clinical Oncology In: , Vol. 32, No. 15, 20.05.2014, p. 1563-1570.
  • "Regorafenib for treatment of advanced gastrointestinal stromal Tumors." Expert Opinion on Pharmacotherapy In: , Vol. 15, No. 4, 03.2014, p. 549-558.
  • "Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer." Clinical Cancer Research In: , Vol. 20, No. 5, 2014, p. 1306-1312.
  • "Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract." Journal of the American Academy of Dermatology  In: , Vol. 71, No. 2, 2014, p. 229-236.
  • "Gastrointestinal Stromal Tumors. Molecular Markers and Genetic Subtypes." Hematology/Oncology Clinics of North America In: , Vol. 27, No. 5, 10.2013, p. 871-888.
  • "Imatinib for melanomas harboring mutationally activated or amplified kit arising on mucosal, acral, and chronically sun-damaged skin." Journal of Clinical Oncology In: , Vol. 31, No. 26, 10.09.2013, p. 3182-3190.
  • "Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia." Molecular Cancer  In: , Vol. 12, No. 1, 46, 24.05.2013.
  • "Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms." Molecular Cancer  In: , Vol. 12, No. 1, 19, 07.03.2013.
  • "Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping." Journal of Molecular Diagnostics In: , Vol. 15, No. 2, 03.2013, p. 171-176.
  • "Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors." Nature Genetics  In: , Vol. 45, No. 2, 02.2013, p. 131-132.

Additional information

Edit profile